Initial in-human experience with the conveyor cardiovascular system for the delivery of large profile transcatheter valve devices

Brian P O'Neill, Dee Dee Wang, Thomas G Caranasos, W Randolph Chitwood Jr, William W O'Neill, Richard Stack

Three patients underwent transcatheter mitral valve replacement with a SAPIEN-3 valve. One patient each underwent transcatheter aortic valve (TAVR) implantation with a SAPIEN 3 and 1 patient underwent TAVR implantation with a Lotus valve. All patients underwent successful implantation of the valve and removal of the CCS and valve delivery systems.

Comparison of a new bioprosthetic mitral valve to other commercially available devices under controlled conditions in a porcine model

Dee Dee Wang, MD; Thomas G. Caranasos, MD; Brian P. O'Neill, MD; Richard S. Stack, MD; William W. O'Neill, MD; W. Randolph Chitwood Jr., MD

Rigorous scientific evaluation of surgical mitral bioprostheses is necessary for patient safety. Based on these results, we would advise caution when evaluating manufacturers' advertising. Implications of this study demonstrate a critical need for standardization and scientific evaluation of surgical mitral bioprostheses to ensure optimal outcomes for clinical human implantation.

Initial in-human experience with the conveyor cardiovascular system for the delivery of large profile transcatheter valve devices.

O'Neill BP; Wang DD; Caranasos TG; Chitwood WR Jr.; O'Neill WW; Stack R.

The CCS may facilitate transcatheter valve delivery in patients who were deemed to have challenging structural anatomy. This pilot study demonstrated the feasibility of incorporating this system with multiple different transcatheter valves. Future studies in a broader representation of patients are warranted.

Comparative differences of mitral valve-in-valve implantation: A new mitral bioprosthesis versus current mosaic and epic valves

Wang DD; O'Neill BP; Caranasos TG; Chitwood WR Jr.; Stack RS; O'Neill WW

The current study demonstrates marked variations in hemodynamics, THV opening area, and anatomic dimensions among measured similarly sized mitral bioprostheses. These data suggest a critical need for understanding the potential impact of variations in bioprosthesis design on TMVR VIV clinical outcomes.